Globeflex Capital’s UroGen Pharma URGN Stock Holding History

Globeflex Capital’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,279	Closed	-$127K	–	510
2022 Q4	$127K	Buy	+14,279	New	+$135K	0.02%	374

Other funds holding URGN

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Globeflex Capital's URGN Position: Q1 2023 in Review

Globeflex Capital sold out of UroGen Pharma (URGN) in Q1 2023, closing a stake of 14,279 shares — an estimated $127K sold.

Globeflex Capital first reported a position in URGN in Q4 2022 and held it in 1 quarter. The position peaked at $127K in Q4 2022. 65 funds tracked by Wall St. Rank hold URGN as of Q1 2023.

Globeflex Capital reported no remaining UroGen Pharma position as of Q1 2023 after selling out during the quarter.
Globeflex Capital sold 14,279 UroGen Pharma shares in Q1 2023, an estimated $127K.
Globeflex Capital first reported a position in UroGen Pharma in Q4 2022 and held it in 1 quarter.
Globeflex Capital's UroGen Pharma position peaked at $127K in Q4 2022.
65 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2023.

Based on Globeflex Capital's 13F filing for Q1 2023, filed 12 May 2023.